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Abstract: In utero haematopoietic stem cell transplantation (IUHSCT) is a non
approach for the prenatal treatment of genetic disorders. However, in target disorders, where 
there is not a selective advantage for donor cells, a useful donor
achieved. There are three  possible  barriers  
space in the fetus due to host-cell competition; the large number of donor cells needed, and 
the immunological asset of recipient .
Introduction: Animal models have shown different 
levels  of  resistance  to  IUHSCT  engraftment.    In 
primate,  goat,  rat  and  mouse    the  levels  of 
engraftment that has been achieved were low and 
not    therapeutic. Among  46  cases  of    IUHSCT 
reported  in  humans,  successful  engraftment    was 
obtained only in cases of  X-SCID. Useful levels of 
chimerism  has  not  been  achieved  in  non
immunodeficiency  diseases,  and    a  detectable 
engrafment , was  reported only in one case  of  ß
thalassemia transplanted at  12  weeks of  gestation
by  fetal  liver  cells.  In  one  -thalassemia  case, 
where  -globin-dependent  hemoglobin  production 
and  anemia  are  present  during  fetal  period, 
microchimerism  and tolerance were suggested
To overcome the IUHSCT engraftment barriers , 
it is necessary to develop strategies to improve the 
competitive capacity of donor cells and  to define 
the  gestational age of the possible immunological 
“window of opportunity” in the human fetus. 
In utero haematopoietic stem cell transplantation 
(IUHSCT)  is  a  non-myeloablative  promising 
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haematopoietic stem cell transplantation (IUHSCT) is a non
approach for the prenatal treatment of genetic disorders. However, in target disorders, where 
there is not a selective advantage for donor cells, a useful donor-cell  chimerism  has 
There are three  possible  barriers  to engraftment following IUHSCT
cell competition; the large number of donor cells needed, and 
the immunological asset of recipient .
Animal models have shown different 
levels  of  resistance  to  IUHSCT  engraftment.    In 
primate,  goat,  rat  and  mouse    the  levels  of 
engraftment that has been achieved were low and 
Among  46  cases  of    IUHSCT 
reported  in  humans,  successful  engraftment    was 
SCID. Useful levels of 
chimerism  has  not  been  achieved  in  non-
immunodeficiency  diseases,  and    a  detectable 
n one case  of  ß-
thalassemia transplanted at  12  weeks of  gestation  
thalassemia  case, 
dependent  hemoglobin  production 
and  anemia  are  present  during  fetal  period, 
microchimerism  and tolerance were suggested. 
To overcome the IUHSCT engraftment barriers , 
it is necessary to develop strategies to improve the 
competitive capacity of donor cells and  to define 
the  gestational age of the possible immunological 
“window of opportunity” in the human fetus. 
haematopoietic stem cell transplantation 
myeloablative  promising 
approach for the prenatal treatment of a variety of 
genetic  disorders  and    could  be  an  alternative  
option to therapeutical abortion in some congenital 
diseases like haematological hereditary  syndromes. 
Observations  of  “naturally”  occurring 
hematopoietic  chimerism
1,  and  of  experimental 
chimeras produced by IUHSCT, have demonstrated 
that allogeneic engraftment of the early gestational 
fetus with donor-specific tolerance is 
Although  IUHSCT  has  been  clinically 
successful  in  severe  combined  immunodeficiency 
disease  (SCID),  a  therapeutic  donnor
chimerism  (more  than  1%)
correction of most diseases, has not been achieved  
in target disorders, like  hemoglobinopathies, where 
there is not a selective advantage for donor cells
The  reasons  for  this  failure  are    unclear  and 
reflect a limited understanding of the engraftment 
barriers involved in clinical IUHSCT.
There are three  possible  barriers  to allogenic 
engraftment following IUHSCT :  limited space in 
the fetus due to host-cell competition from a robust 
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Observations  of  “naturally”  occurring 
,  and  of  experimental 
chimeras produced by IUHSCT, have demonstrated 
that allogeneic engraftment of the early gestational 
specific tolerance is possible
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Although  IUHSCT  has  been  clinically 
successful  in  severe  combined  immunodeficiency 
disease  (SCID),  a  therapeutic  donnor-cell  
chimerism  (more  than  1%)
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correction of most diseases, has not been achieved  
ke  hemoglobinopathies, where 
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The  reasons  for  this  failure  are    unclear  and 
reflect a limited understanding of the engraftment 
barriers involved in clinical IUHSCT.
There are three  possible  barriers  to allogenic 
engraftment following IUHSCT :  limited space in 
cell competition from a robust Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
and  highly  proliferative  fetal  hematopoietic 
compartment;  the  large  number  of  donor  cells 
needed  to successfully compete with host cells for 
these sites; and the immunological asset of recipient 
that  determines  the  grade  of    the  possible  fetal 
tolerance which is conditional, depending on timing 
and appropiate presentation of antigen
4.                
The last barrier has been supported by successful 
allogenic  IUHSCT  in  sheeps  and  monkeys
5
occurred  if  donor  and  recipient  fetuses  are  in  a 
preimmune condition, by  the presence of high-level 
engraftment  after  IUHSCT  in  disorders    where 
exists a competitive or survival advantage for donor 
cells,  and  by  the  presence  of  VDJ  TCR  ß  chain 
transcript since the 7
th weeks of gestation
6.
The  goal  of    therapeutically  relevant  levels  of 
chimerism  following  a  single  in  utero 
transplantation  has  been  difficult  to  achieve.  The 
induction of tolerance with low levels of chimerism 
to facilitate postnatal cellular  transplantations using 
minimally ablative conditioning regimens is a more 
realistic goal for clinical application of IUHSCT.
  
Cell sources: Hematopoietic stem cells (HSC) have 
been isolated from fetal liver
7, umbilical cord blood, 
adult bone marrow
8 and mobilized peripheral blood. 
HSC  isolated  from  these  sources  were  well 
described for their capacity  to generate mature cells 
of all lymphohematopoietic lineage and their self-
renewal capacity.
All these cell sources were employed to perform 
IUHSCT; however, if postnatal cellular therapy is 
needed,  the  donor  cells  must  be  obtained  from  a 
renewable source as adult related bone marrow or 
mobilized peripheral blood
9.
Animal models: An ‘‘experiment of nature’’ first 
described by Owen in 1945 is the best supporting 
evidence  that  IUHSCT  might  work  :    dizygotic 
cattle  twins  that  share  cross-placental  circulation 
were  born  chimeric  for  their  sibilings  blood 
elements, and this state of ‘‘chimerism’’ persisted 
for life  and  was  associated  with  specific
transplantation tolerance
1.
The  first    animal  model  was  the  sheep.  Early 
gestational transplantation of allogenic, fetal liver–
derived HSC into normal sheep fetuses resulted in a 
multilineage  hematopoietic  chimerism
10 that 
persisted for many years and  ranged from  10% to 
15%  donor cell expression
11.
Other  normal  animal  models    have  shown 
different levels of  resistance to engraftment after in 
utero transplantation.  In the normal primate, goat, 
rat and mouse (12-16) the levels of engraftment that 
has been achieved were low and not  therapeutic: 
successful allogenic IUHSCT in monkeys occurred 
if donor and recipient fetuses are in a preimmune 
condition
17.
Almeida-Porada et al. 2000,  used the in utero 
model  of  human–sheep  HSC  transplantation  to 
investigate ways  of  improving  engraftment  and 
differentiation of donor cells after transplantation
18. 
In  this  xenogeneic  model,  the  authors  co-
transplanted HSC and bone marrow-derived human 
stromal cells  obtaining  an  enhancement  of  long-
term  engraftment  of  human  cells  in  the  bone 
marrow of the chimeric animals and  higher levels 
of donor cells in circulation both during gestation 
and after birth.
Hayashi et al 2002, obtained the  induction of  
prenatal  tolerance  in  mice  where  a  combined 
approach of  IUHSCTx, performed by intraperitonel 
injection,  followed by postnatal donor lymphocyte 
infusion  has  converted  low-level  mixed 
hematopoietic  chimerism  to  complete  donor 
chimerism
19. 
A mouse model described by Perenteau et al
20  
strongly support the presence of  an immune barrier 
to allogeneic engraftment after IUHSCT . Four-teen 
weeks old  fetal mice were transplanted with high 
doses  of  donor  cells    of  either  allogeneic  or 
congenic  bone  marrow,  using    intravascular  
injection technique. Engrafment was lost in 70% of 
allogeneic recipients by 1 month of age; in contrast, 
all congenic recipients maintain stable, long-term, 
multilineage  chimerism,  thus  giving  a  strong 
evidence for an  innate immune mechanism , natural 
killer  cell  or  macrophage  mediated,    able  to 
eliminate  allogeneic cells  after IUHSCT
20. 
However,  further  studies  are  needed  to  better 
characterize  the  timing  of  human  fetal    NK-cell 
maturation. 
The  reasons  for  the  failure    in  the  correction 
most  diseases  and  the  absence  of  predicting  
tolerance  in  absence of immunosuppression, both 
in human or animal models, of IUHSCT  are  still 
unclear  and reflect a limited understanding of the 
engraftment barriers
21.
IUHSCT  in  Humans:    Since  Touraine  et al 
published  the  first  instance  of  intrauterine 
transplantation in  a  human fetus  affected  by bare 
lymphocyte syndrome (BLS)  in 1989
22, 46 cases of  
IUHSCT  in  human  for  various  indications  have 
been  reported
23 with  different  timing  of 
transplantation, source of donor cells and the target 
disease.  Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
However,  successful  well-documented 
engraftment  after  in  utero  therapy  was  obtained 
only in cases of  X-linked SCID by Touraine , Flake  
and Wengler
24-26. 
Useful  levels  of  chimerism  has  not  been 
achieved  in  non-immunodeficiency  diseases,  as 
metachromatic  leukodystrophy
27,  chronic  granulo-
matous disease (Flake, unpublished data, 1995) or 
-thalassemia major
24,27-29.
Particularly,  a  detectable  engrafment  ,  using 
IUHSCT,  was  reported  only  in  one  case    of 
thalassemia  major  transplanted  at  12  weeks  of 
gestation by fetal liver cells
30. In this case transitory 
engrafment was documented  by  the presence of 
the  Y  chromosome  of  donor  origin    but  not 
erythroid microchimerism
30.
Only in one -thalassemia case, transplanted at 
13  weeks  of  gestation  with  paternal  CD34+ 
enriched cells, microchimerism and tolerance were 
suggested
31 . However, the prenatal hematopoietic 
biology of the  and -thalassemia are different. In 
the  case  of  - thalassemia,  -globin-dependent 
hemoglobin  production  (HbF)  and  anemia  are 
present during fetal period and this could determine 
a  selective  advantage  for    the  donor-derived  
haematopoietic  stem  cells .  Instead,      in  -
thalassemia  the  selective  advantage  could  be  not 
present  because  of  globin  chain  synthesis 
impairement and  anemia do not occur until after 
birth.
Our  experience,  in    cases  treated  between  the 
13
th and the  18
th weeks  of  gestation  using 
cryopreserved  fetal  liver  haematopietic  stem  cells 
and  without  immunodepression, was  also 
unsuccessful
29.  
Particularly,  a  fetus, affected  by  ß-thalassemia 
major    who  underwent  a  fetus-to-fetus 
transplantation  between the 14
th  and the 20
th  week 
of gestation, generated an alloimmune response as 
demonstrated by an high cytotoxic  T cell precursor 
(CTLp) frequency against donor cells
32.
We  set-up  a  clinical  protocol  by  which  two 
female fetuses, 16-20 weeks old, were transplanted 
with  circulating  hematopoietic paternal  stem cells 
after  one  week  of  low  dose  dexamethasone 
treatment with the aim to overcome the engraftment 
barrier by inducing a transient mild fetal immuno 
suppression and induce a donor-specific tolerance. 
During  these  procedures  no  adverse  events  were 
observed  both for  the mothers and the fetuses. At 
birth,  both  fetuses  showed  the  presence  of  Y 
chromosome of donor origin but only  one,  at two 
months  of  age,  showed  the  presence  of  paternal 
blood group allele A cDNA in peripheral blood  and 
an  increase  of  HbA  concentration  from  3%  to 
14.4%,  suggesting  that  erithroid  microchimerism 
has been occurred. At 5 months of age haemoglobin 
decreased to 6.8 g/dl and the girl started a  regular 
blood  transfusional  regimen
33.  This  could  be 
explained only by a transitory engraftment of donor 
cells  as  it  was  previously  shown  in  the  case 
described by Touraine
30.
IUHSCT:  future  perspectives: To  overcome  the 
barriers  that  hinder the success of IUHSCT, it is 
necessary  to  develop  strategies  to  improve  the 
competitive  capacity  of  donor  cells  to  achieve 
significant  engraftment,  and    to  define  the 
gestational  age  of  the  possible  immunological 
“window of opportunity” in the human fetus. 
A  significant  barrier  to  allogeneic  engraftment 
following IUHSCT is limited space in the fetus due 
to  host-cell competition from a robust and highly 
proliferative  fetal  hematopoeitic  compartment  in 
circumstances  where  a  competitive  or  survival 
advantage  does  not  exist  for  donor  cells
34.
Additionally,  the  inability  of  HSC  to  home  and 
engraft  with  absolute efficiency may limit  donor-
cell engraftment following allogeneic IUHSCT.
Thus,  strategies that  selectively  increase  donor 
HSC homing and engraftment in the fetal recipient 
may  increase  both  the  levels  and  frequency  of 
engraftment  following  allogeneic  IUHSCT.
Dipeptidyl peptidase CD26 inhibition may represent 
a  novel  approach  to  increasing  the  efficacy  and 
success of HSC/HPC transplantation
35. 
Recent in  vitro studies have demonstrated that 
increased  cleavage  of  stromal-derived  factor  1 
(SDF-1)  by  CD26,  a  chemokine  involved  in 
hematopoietic  cell  chemotaxis,  homing, 
mobilization  and  survival,  results  in  a  loss  of  its 
chemotactic effect on primitive hematopoietic cells. 
Instead,  its  inhibition  results  in  SDF1–induced 
migration
36. 
In  vivo,  postnatal  studies  in  a  murine  bone 
marrow  transplantation  (BMT)  model  found 
increased short-term bone marrow (BM) homing of 
enriched HSC and low-density BM donor cells after 
inhibition or absence of CD26 activity. Reduction 
of  CD26  activity  on  low-density  donor  BM  cells 
also  resulted  in  increased  long-term  engraftment, 
competitive  repopulation,  secondary  trans-
plantation,  and  mouse  survival  following  lethal 
irradiation. Therefore, CD26 inhibition may be an 
important  adjunct  to  other  strategies  that  are 
directed  toward  overcoming  the  barriers  to  fetal 
engraftment
37.  The  demonstration  that  transient 
manipulation of a single chemokine interaction can Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
result  in  improvements  in  engraftment  is 
encouraging, as there are many steps in the homing 
and  engraftment  process  that  could  potentially be 
manipulated,  singly  or  in  combination,  to 
significantly improve engraftment
38. 
Other  manipulations  that  selectively  influence 
expression  of  homing  receptors  and  engraftment 
include cotransplantation with  stroma. The use of 
stromal cotransplantation has increased short- and 
long-term  donor  cell  expression  in  the  sheep 
model
39,40.  Human-placenta–derived  mesenchymal 
stem  cells  (MSC)  show  a  mutilineage 
differentiation  capacity  and  they  have  a  direct 
immunosoppressive  effect  on  proliferation  of  T 
lymphocytes  from peripheral blood and umbilical 
cord blood. Even if the way that human-placenta –
derived  MSC  modulate  the  immune  system  is 
unclear,  this immunoregulatory feature implies that 
human-placenta–derived  MSC  have  a  potential 
application in allograft transplantation
41. 
Therefore, the recognition of an immune barrier 
suggests  potential  immune-based  strategies for 
application to IUHSCT that might prevent loss of 
engraftment. 
Some studies in mice
19,42 support the existence 
of the phenomenon of fetal tolerance  that it may be 
dependent on timing and appropriate presentation of 
antigen.  Moreover,  there  are    extrathymic
16
mechanisms of rejection  (NK – or B-cell-mediated 
response) that are  poorly understood.  In the human 
fetus there is evidence of immunocompetence from 
at least the 11
th week of gestation  suggested by the  
presence  of  alloreactive  T  lymphocytes  from  the 
10
th week  of  gestation  that    could  explain  the  
failure  of  engraftment  in  fetuses  older  than  this 
gestation
6,28,32.  Therefore  ,  IUHSCT  should  be 
performed  before  the  10
th week  of  gestation. 
However, at this so early gestation it is impossible 
to carry out the infusion of CD34 into the umbilical 
cord by intravascular route or by their infusion into 
intraperitoneal  cavity  .  One  possible  future 
approach could the infusion of these cells into the 
coelomic cavity. 
Coelocentesis  at  6-10 weeks  of  gestation    has 
been successfully used to obtain fetal DNA for very 
early prenatal diagnosis of genetic diseases
43-45 The 
celomic cavity is now believed to be an important 
transfer interface and a reservoir of nutrients for the 
embryo and it is present since the fourth week after 
the last menstruation. Therefore, this cavity could 
be a new route of access to the fetus. In our study of 
celomic fluid from fetuses sampled from 6.6 to 10 
weeks  of  gestation  by  coelocentesis  we  found  an 
immunological  pattern  showing  a  very  low 
frequency of the T, pre-B, B lymphocytes, NK and 
CD34+ cells. Moreover, the analysis of rearranged 
VDJ  TCR  β  chain  transcripts  and  TCR  α  chain 
transcripts  showed  the  presence  of  only  PreTα 
expression and only 40% (7 of 17) samples showed 
the  presence of  some  V-subfamilies  suggesting 
that the coelomic cavity could be a useful route of 
CD34+  cells  infusion  for  “in  utero 
transplantation”
46. 
The injection of donor haematopoietic stem cells 
into this cavity could potentially induce tolerance in 
the  fetus making  successive  booster  stem  cells 
infusions possible. This  procedure has already been 
evaluated in pre-immune fetal sheep in which the 
injection of human stem cells through the coelomic 
cavity  was  associated  with  a  significant  level  of 
engraftment
47. 
Conclusions: The  intrauterine  approach  was 
criticized  by  several  authorities  in  this  field  who 
claimed  that  this  approach  did  not  offer  any 
advantage over postnatal transplantation. The main 
arguments against intrauterine transplantation were 
that  the  fetal  invasive procedure carried  a  certain 
additional risk.
Conversely,  promoters  of  intrauterine 
transplantation  claimed  that  reconstitution  of  the 
immune  system  before  birth  results  in  reduced 
susceptibility to  infections in  the  neonatal period, 
and to an improved psychosocial situation  for the 
family.  Other  potential  advantages  for  an 
intrauterine  approach  include  cost  savings  and  a 
reduced risk of GVHD in the fetal environment.
Thus, a consensus has been difficult to reach and 
fetal transplantation has not been widely adopted, 
despite the fact that successful cases treated in utero 
had  outcomes  comparable  with  the  best  reported 
with postnatal transplantation
48.
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